Skip to main content

Advertisement

SpringerLink
Log in

Recurrent skin infections associated with natalizumab treatment

  • Letter to the Editor
  • Published:
Neurological Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Butzkueven H et al (2020) “Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)”, (in eng). J Neurol Neurosurg Psychiatry 91(6):660–668. https://doi.org/10.1136/jnnp-2019-322326

    Article  PubMed  Google Scholar 

  2. Niino M et al (2006) “Natalizumab effects on immune cell responses in multiple sclerosis”, (in eng). Ann Neurol 59(5):748–754. https://doi.org/10.1002/ana.20859

    Article  CAS  PubMed  Google Scholar 

  3. Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B (2020) “Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring”, (in eng). Front Immunol 11:549842. https://doi.org/10.3389/fimmu.2020.549842

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Geherin SA, Gómez D, Glabman RA, Ruthel G, Hamann A, Debes GF (2016) “IL-10+ innate-like B cells are part of the skin immune system and require α4β1 integrin to migrate between the peritoneum and inflamed skin”, (in eng). J Immunol 196(6):2514–2525. https://doi.org/10.4049/jimmunol.1403246

    Article  CAS  PubMed  Google Scholar 

  5. (2021) Tysabri (natalizumab) prescribing information. [Online] Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125104s973s975lbl.pdf. Accessed 2 Feb 2022

  6. Vennegoor A et al (2013) “Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis”, (in eng). Mult Scler 19(5):593–600. https://doi.org/10.1177/1352458512460604

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

DO and RC declare they have no financial interests. LR has received an unrestricted research grant from Biogen and consulting fees from Biogen, Roche, Novartis and Sanofi.

Author information

Authors and Affiliations

  1. Serviço de Neurologia, Centro Hospitalar de Entre o Douro e Vouga, Rua Dr. Cândido Pinho, No. 5, 4520-220, Santa Maria da Feira, Portugal

    Daniela Santos Oliveira, Ana Rita Castro & Luís Ruano

  2. Instituto de Saúde Pública, Universidade do Porto, Rua das Taipas, No. 135, 4050-600, Porto, Portugal

    Luís Ruano

  3. Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Rua das Taipas, No. 135, 4050-600, Porto, Portugal

    Luís Ruano

  4. Faculdade de Medicina da Universidade do Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal

    Luís Ruano

Authors
  1. Daniela Santos Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Rita Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luís Ruano
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DO: writing—original draught, visualization. RC: writing—original draught. LR: writing—review and editing, supervision.

Corresponding author

Correspondence to Daniela Santos Oliveira.

Ethics declarations

Ethics approval

Approval was obtained from the ethics committee of Centro Hospitalar de Entre o Douro e Vouga. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Consent

The participant has consented to the submission of the full content of the case report to the journal.

Conflict of interest

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oliveira, D.S., Castro, A.R. & Ruano, L. Recurrent skin infections associated with natalizumab treatment. Neurol Sci 44, 1093–1095 (2023). https://doi.org/10.1007/s10072-022-06481-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-022-06481-2

Search

Navigation